Changchun Bcht Biotechnology Co. Class ASSE: 688276

Announcement on Voluntary Disclosure of Obtaining Approval of Clinical Trial for Split-Virion Influenza Vaccine (BK-01 Adjuvant)

· Issued by Changchun Bcht Biotechnology Co. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Approval of Clinical Trial for Split-Virion Influenza Vaccine (BK-01 Adjuvant)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis